Document Detail

Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.
MedLine Citation:
PMID:  19954718     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Postmenopausal women undergoing chronic hemodialysis are at risk of uremic bone disease and postmenopausal osteoporosis. There are few reports discussing the effects of raloxifene hydrochloride on chronic hemodialysis patients. We investigated whether differences in the effects of raloxifene on bone mineral density (BMD) are dependent on the level of intact parathyroid hormone (iPTH). METHODS: 47 postmenopausal hemodialysis patients with osteoporosis were divided into two groups, i.e. Group A, with treatment, and Group B, without treatment by raloxifene hydrochloride (60 mg/day, three times per week) for 1 year. We evaluated the changes in BMD at the distal one-third of the radial bone and aortic calcification index (ACI) by plain abdominal computerized tomography. Furthermore, we compared the BMD and ACI results for patients with similar iPTH levels within each group. RESULTS: After 1 year of raloxifene treatment, patients with iPTH levels of < 250 pg/ml in Group A showed significantly less BMD deterioration than similar patients in Group B (A: -0.31 +/- 1.7% vs. B: -3.71 +/- 0.7%, p = 0.04). However, raloxifene showed no difference in patients with iPTH levels of > or = 250 pg/ml in the two groups (A: -3.49 +/- 0.7% vs. B: -6.10 +/- 1.9%, p = 0.09). Among the patients with iPTH levels of < 250 pg/ml, changes in the ACI values were 1.30 +/- 0.3% for Group A and 1.67 +/- 1.0% for Group B. Among the patients with iPTH levels of (3) 250 pg/ml, the ACI values were 2.58 +/- 0.7% for Group A and 3.01 +/- 1.2% for Group B. CONCLUSIONS: Raloxifene treatment was useful for the prevention of BMD deterioration in postmenopausal dialysis patients with controlled iPTH levels.
R Eriguchi; J Umakoshi; S Miura; Y Sato
Related Documents :
21532428 - Audiologic findings in saethre-chotzen syndrome.
2731608 - Respiratory aspects of shwachman's syndrome in adults.
21156248 - The t(6;9)(p22;q34) in myeloid neoplasms: a retrospective study of 16 cases.
10197258 - Loss of the y chromosome in bone marrow cells: results on 1907 consecutive cases of leu...
19843438 - Can patterns of segmental injuries of the foot and ankle predict amputation and disabil...
8088268 - Relationship of renin, angiotensin ii and atrial natriuretic factor to clinical status ...
Publication Detail:
Type:  Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  72     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-03     Completed Date:  2010-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  423-9     Citation Subset:  IM    
Sato Junkanki Hospital, 4-10-25 Asouda-cho, Matsuyama City, Ehime Prefecture, 790-0952, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Bone Density
Bone Density Conservation Agents / administration & dosage,  therapeutic use*
Disease Progression
Dose-Response Relationship, Drug
Follow-Up Studies
Immunoradiometric Assay
Kidney Failure, Chronic / blood,  therapy*
Middle Aged
Osteoporosis, Postmenopausal / blood,  drug therapy*,  etiology
Parathyroid Hormone / blood*
Raloxifene / administration & dosage,  therapeutic use*
Renal Dialysis / adverse effects*
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Bone Density Conservation Agents; 0/Parathyroid Hormone; 84449-90-1/Raloxifene

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers.
Next Document:  Management of young patients with lupus nephritis using tacrolimus administered as a single daily do...